Nebulised furosemide for the treatment of patients with obstructive lung disease: a systematic review protocol.
asthma
chronic airways disease
emphysema
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
23 Nov 2023
23 Nov 2023
Historique:
medline:
27
11
2023
pubmed:
24
11
2023
entrez:
23
11
2023
Statut:
epublish
Résumé
Obstructive lung diseases (OLDs) such as asthma and chronic obstructive pulmonary disease are major global sources of morbidity and mortality. Current treatments broadly include bronchodilators such as beta agonists/antimuscarinics and anti-inflammatory agents such as steroids. Despite therapy patients still experience exacerbations of their diseases and overall decline over time. Nebulised furosemide may have a novel use in the treatment of OLD. Multiple small studies have shown improvement in pulmonary function as well as dyspnoea. This systematic review will aim to summarise and analyse the existing literature on nebulised furosemide use in OLD to guide treatment and future studies. We will identify all experimental studies using nebulised/inhaled furosemide in patients with asthma or chronic obstructive pulmonary disease that report any outcome. Databases will include EMBASE, MEDLINE, Cochrane Database of Systematic Reviews, ACP Journal Club, Database of Abstracts of Reviews of Effects, Cochrane Clinical Answers, Cochrane Central Register of Controlled Trials, Cochrane Methodology Register, Health Technology Assessment and the NHS Economic Evaluation Database (1995-2015). We will also search ClinicalTrials.gov and the WHO-International Clinical Trials Registry Platform. Two reviewers will independently determine trial eligibility. For each included trial, we will perform duplicate independent data extraction, risk of bias assessment and evaluation of the quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. Ethical approval will not be applicable to this systematic review. The results of the study will be communicated through publication in peer-reviewed journals. CRD42021284680.
Identifiants
pubmed: 37996224
pii: bmjopen-2022-070155
doi: 10.1136/bmjopen-2022-070155
pmc: PMC10668269
doi:
Substances chimiques
Furosemide
7LXU5N7ZO5
Bronchodilator Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e070155Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):971-5
pubmed: 10988115
Syst Rev. 2012 Feb 09;1:2
pubmed: 22587842
Thorax. 2008 Jul;63(7):606-13
pubmed: 18250181
Respir Care. 2013 Nov;58(11):1873-7
pubmed: 23650431
N Engl J Med. 2022 Jan 13;386(2):157-171
pubmed: 35020986
Respir Physiol Neurobiol. 2007 Apr 16;156(1):1-8
pubmed: 16935035
Respir Physiol. 2001 Mar;125(1-2):17-31
pubmed: 11240150
Ann Med Surg (Lond). 2020 Jul 18;57:85-90
pubmed: 32728436
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Proc Am Thorac Soc. 2005;2(4):355-60; discussion 371-2
pubmed: 16267362
J Pain Symptom Manage. 2008 Oct;36(4):424-41
pubmed: 18468839
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
J Asthma Allergy. 2022 Apr 05;15:407-418
pubmed: 35411151
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880
Am J Respir Crit Care Med. 2000 Jun;161(6):1963-7
pubmed: 10852774
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Lancet. 2011 Jan 8;377(9760):108-9
pubmed: 20630580
Am J Ther. 2002 Jul-Aug;9(4):317-28
pubmed: 12115021
Pulm Pharmacol Ther. 2008;21(1):196-200
pubmed: 17428714
Respir Med. 1991 Sep;85 Suppl B:25-31; discussion 33-7
pubmed: 1759018
Front Physiol. 2018 Feb 12;9:86
pubmed: 29483879
BMJ. 2006 Sep 16;333(7568):597-600
pubmed: 16974018
Respir Physiol. 2001 Mar;125(1-2):33-45
pubmed: 11240151
Int J Evid Based Healthc. 2015 Sep;13(3):196-207
pubmed: 26355603
Respir Res. 2018 Sep 20;19(1):181
pubmed: 30236110
J Pain Symptom Manage. 2003 Oct;26(4):962-7
pubmed: 14575057
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
J Clin Epidemiol. 2011 Apr;64(4):383-94
pubmed: 21195583